The Invisible Barrier: Why Starting New Medications Is a Crisis for the Chronically Ill on August 11, 2026 Posted by
Beyond the Scale: How Time-Restricted Eating May Sharpen the Aging Brain on August 11, 2026 Posted by
Navigating the Invisible Minefield: A Comprehensive Guide to Identifying and Managing Bipolar Triggers on August 11, 2026 Posted by
Bridging the Care Gap: Inside the Collaboration Between NYU Langone and Dana-Farber to Redefine Oncology Software on August 11, 2026 Posted by
The Silent Crisis of Iatrogenic Trauma: Reclaiming Agency in the Shadow of Psychiatric Overmedication on August 11, 2026 Posted by
Championing the Future of Longevity: The Alliance for Aging Research Releases 2025 Impact Report on August 11, 2026 Posted by
The Invisible Barrier: Why Starting New Medications Is a Crisis for the Chronically Ill on August 11, 2026 Posted by
Beyond the Scale: How Time-Restricted Eating May Sharpen the Aging Brain on August 11, 2026 Posted by
Navigating the Invisible Minefield: A Comprehensive Guide to Identifying and Managing Bipolar Triggers on August 11, 2026 Posted by
Posted in Cardiovascular Recovery Preventive Cardiology Breakthrough: PCSK9 Inhibitor Evolocumab Shows Promise for High-Risk Diabetes Patients on August 7, 2026
Posted in Medical Innovations A New Frontier in Cardiology: FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor on July 17, 2026
Posted in Medical Innovations A New Era in Cardiology: FDA Greenlights Enlicitide, the First Oral PCSK9 Inhibitor on July 16, 2026
Posted in Digital Health Tools Roche Claims Breakthrough in Lung Cancer Treatment with Next-Generation KRAS Inhibitor on July 3, 2026
Posted in Digital Health Tools A New Frontier in Myelofibrosis: Eli Lilly’s Novel JAK2 Inhibitor Shows Promise in Early Trials on June 21, 2026
Posted in Medical Innovations Setback in the Quest for a Parkinson’s Breakthrough: Biogen and Denali’s LRRK2 Inhibitor Fails Mid-Stage Trial on May 24, 2026 rifanmuazin
Posted in Digital Health Tools A Stalled Frontier: The Clinical Failure of Biogen and Denali’s LRRK2 Inhibitor in Parkinson’s Disease on May 22, 2026 rifanmuazin
Posted in Cardiovascular Recovery A New Frontier in Hypertension: FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor on May 19, 2026 rifanmuazin
Posted in Digital Health Tools A New Frontier in Oncology: FDA Approves Beqalzi as First-in-Class BCL-2 Inhibitor for Mantle Cell Lymphoma on May 15, 2026 rifanmuazin
